Core Viewpoint - Onconetix, Inc. has received approval from the Nasdaq Hearings Panel for continued listing on The Nasdaq Stock Market, contingent upon compliance with specific Nasdaq Listing Rules by set deadlines [1][2]. Group 1: Compliance and Listing Status - On June 11, 2025, Onconetix was granted a decision for continued listing, requiring compliance with the Periodic Filing Listing Rule by June 13, 2025, and the Bid Price Listing Rule by June 30, 2025 [1]. - The company demonstrated compliance with the Periodic Filing Listing Rule on June 12, 2025, by filing the Form 10-Q for the period ended March 31, 2025 [2]. - A 1-for-85 reverse stock split of its outstanding shares was completed on June 13, 2025, to help meet listing requirements [2]. Group 2: Company Overview - Onconetix, Inc. is a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology [3]. - The company owns Proclarix, an in vitro diagnostic test for prostate cancer, which is approved for sale in the European Union [3].

Core Viewpoint - RAPT Therapeutics, Inc. announced a 1-for-8 reverse stock split effective June 16, 2025, aimed at consolidating its outstanding shares to potentially enhance its stock price and market perception [1][2]. Company Overview - RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunological diseases [5]. Reverse Stock Split Details - The reverse stock split will reduce the number of issued and outstanding shares from approximately 132.3 million to approximately 16.5 million [4]. - The reverse stock split will be effective at 11:59 pm Eastern Time on June 16, 2025, with trading on a reverse stock split-adjusted basis starting June 17, 2025 [1][2]. - Every eight issued and outstanding shares will be combined into one share without changing the par value per share, and fractional shares will not be issued [3]. - Stockholders entitled to fractional shares will receive a cash payment instead [3]. - The total number of authorized shares will remain at 500 million, but the number available for future issuance will increase [3]. Impact on Stockholders - The reverse stock split will affect all stockholders uniformly and will not alter their relative interest in the company's equity securities, except for adjustments related to fractional shares [3].

Group 1 - Shuttle Pharmaceuticals Holdings, Inc. will implement a reverse stock split effective June 16, 2025, at 12:01 a.m. Eastern Time, with the common stock continuing to trade under the symbol "SHPH" on Nasdaq [1][2] - The reverse stock split will convert every 25 shares of the Company's common stock into 1 share, reducing the total number of outstanding shares from approximately 26,210,037 to about 1,048,401 shares [2] - This action is part of Shuttle's strategic plan to comply with Nasdaq's continued listing requirements and to strengthen the Company's long-term capital structure [3] Group 2 - Shuttle Pharmaceuticals is focused on improving outcomes for cancer patients undergoing radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [4] - The Company aims to increase cancer cure rates, prolong patient survival, and improve quality of life through the development of radiation sensitizers, which can be used alone or in combination with other treatments [4]

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has announced a proposed reverse stock split of its common stock at a ratio of 25-for-1, subject to Nasdaq approval, aimed at maintaining compliance with listing requirements and strengthening its capital structure [1][3]. Group 1: Reverse Stock Split Details - At the effective time of the reverse stock split, every 25 shares of the Company's common stock will be combined into 1 share, reducing the total number of shares from 26,210,037 to approximately 1,048,401 shares [2]. - The reverse stock split will also apply to common stock issuable upon the exercise of outstanding RSU grants and warrants, with no fractional shares issued; fractional entitlements will be rounded up to the next highest whole number [2]. Group 2: Company Overview - Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy [4]. - The Company's mission is to enhance the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates, prolong patient survival, and improve quality of life [4].

Core Viewpoint - Opendoor Technologies has seen a significant decline in its stock price and market cap, moving from a peak valuation of over $20 billion to approximately $413 million, indicating a loss of investor confidence in its business model [1][2]. Business Model and Market Conditions - Opendoor's primary business involves purchasing homes, making repairs, and reselling them, but recent market conditions have been unfavorable due to cooling real estate prices and rising interest rates, which have disrupted its cost structure [4][10]. - The company reported over $5 billion in revenue over the past year, but profitability has been challenging due to the slow real estate market and high interest rates, leading to a 13% decline in gross profit year over year [2][10]. Recent Developments - Opendoor announced plans for a reverse stock split to maintain its Nasdaq listing, as its share price has fallen below $1, with a proposed ratio between 1-for-10 and 1-for-50 [5][6]. - The company has shown some operational resilience, buying 3,600 homes in the first quarter, a 4% increase year over year, and selling homes for a total of $1.2 billion, exceeding its guidance [9]. Future Outlook - Management anticipates a significant revenue increase in the second quarter, projecting between $1.45 billion and $1.525 billion, along with positive adjusted EBITDA, although there are concerns about the sustainability of this growth given macroeconomic factors [11][12]. - The reverse stock split does not necessarily indicate the end for Opendoor, but the company must demonstrate a sustainable business model to regain investor confidence [13].

Core Viewpoint - Plug Power's stock surged by 13% as investors received positive signals regarding the company's potential to avoid a reverse stock split, which could negatively impact investor morale [1]. Group 1: Company Actions - Plug Power has proposed to increase the number of authorized shares from 1.5 billion to 3 billion in its preliminary proxy statement for the upcoming annual general meeting [3]. - The company is also seeking approval for a reverse stock split with a ratio between 1-for-5 and 1-for-200, as it struggles to generate profits from its fuel cell and hydrogen sales [3]. - With the current share count nearing 1.1 billion, Plug Power must either authorize more shares or implement a reverse split to maintain its operations [3]. Group 2: Investor Sentiment - Investors are encouraged by Plug Power's assurances that increasing the ceiling on shares outstanding could help the company avoid a reverse stock split [4]. - This positive sentiment among investors is reflected in the rising stock price of Plug Power [5].

Core Viewpoint - Vaxart, Inc. is urging stockholders to vote in favor of a reverse stock split proposal to maintain compliance with Nasdaq listing requirements, with a deadline for voting set for June 1, 2025 [1][16]. Group 1: Reverse Stock Split Proposal - The Board of Directors adjourned the Annual Meeting to give stockholders more time to understand the implications of the reverse stock split, especially in light of a potential delisting from Nasdaq [2]. - The reverse stock split is proposed to help regain compliance with Nasdaq's minimum bid price requirement, with a high end of 1-for-20 split ratio being considered [4]. - A proportional reduction in authorized shares will be proposed alongside the reverse stock split to align with investor feedback [3]. Group 2: Financial Strategy and Capital Raising - Vaxart raised $40 million through an underwritten offering to extend its cash runway, as its previous cash guidance was less than six months [8]. - The company has been proactive in exploring partnerships to avoid dilutive financings, although more data is needed to advance discussions [11]. Group 3: Operational Updates and Future Plans - Vaxart is advancing multiple clinical programs, including norovirus and COVID-19 vaccines, which are expected to drive investor interest [5]. - The company has filed broad patent applications for its oral vaccine technology, which is designed to be administered in pill form [17].

Core Points - Ekso Bionics Holdings, Inc. has updated the effective date of its reverse stock split from May 27, 2025, to June 2, 2025, at a ratio of 1-for-15 [1] - The number of outstanding shares will decrease from approximately 35.5 million to about 2.4 million post-split [2] - The reverse stock split was approved by stockholders to raise the per share trading price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 for ten consecutive trading days [3] Summary by Sections Reverse Stock Split Details - The reverse stock split will not result in fractional shares; any fractional shares will be rounded up to the next whole share [4] - All issued and outstanding shares will be affected, reducing the number of shares issuable upon the exercise of stock options and increasing respective exercise prices [5] Stockholder Information - Stockholders holding shares electronically will not need to take action as their shares will be automatically adjusted [6] - Shareholders with physical certificates can contact VStock Transfer, LLC for information on exchanging their certificates [6] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]

Core Viewpoint - Vaxart, Inc. is urging stockholders to vote in favor of a reverse stock split proposal to avoid delisting from Nasdaq, with support from leading independent proxy advisory firms ISS and Glass Lewis [1] Group 1: Proposal Details - The board of directors has approved two items contingent on the passage of Proposal 2, emphasizing the importance of maintaining the Nasdaq listing for stockholder liquidity and attracting institutional investors [1] - Stockholders who previously voted against Proposal 2 can change their vote by the deadline of May 20, 2025, at 11:59 p.m. Eastern Time [1] Group 2: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform, which allows for storage and shipping without refrigeration [3] - The company's vaccine development programs include oral vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [3] - Vaxart has filed broad domestic and international patent applications for its oral vaccination technology [3] Group 3: Stock Split Information - The current authorized number of shares will be proportionally reduced according to the reverse stock split ratio, which will not exceed 1-for-20 [5]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $20.9 million, a significant increase from $2.2 million in Q1 2024, primarily driven by the BARDA contract awarded in June 2024 [22][23] - The company ended Q1 2025 with cash, cash equivalents, and investments totaling $41.9 million, with an expected cash runway into Q1 2026 [23] Business Line Data and Key Metrics Changes - The COVID-19 vaccine program has resumed activities following the lifting of the stop work order, with patient screening underway and dosing expected to start in Q2 2025 [5][12] - Enrollment in the Phase 1 trial for the norovirus vaccine was completed quickly, with top-line data expected in mid-2025 [8][15] Market Data and Key Metrics Changes - The company is actively pursuing strategic partnerships to enhance funding and support for its clinical programs, particularly in the norovirus and avian flu vaccine markets [17][19] Company Strategy and Development Direction - The company emphasizes the importance of vaccines in public health and aims to innovate oral pill vaccines that can provide effective and durable protection against infections [9][19] - A reverse stock split is being considered as a measure to maintain NASDAQ listing compliance, with management acknowledging the need for a strategic approach to regain investor confidence [26][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the COVID-19 program's potential and the importance of timely communication with stakeholders, despite contractual limitations [5][6] - The company is navigating challenges in the biotech environment and has made workforce reductions to streamline costs and maximize future opportunities [10][23] Other Important Information - The CFO, Phil Lee, announced his resignation for personal reasons, with Jerome Grossman set to take over [10][11] - The avian flu vaccine program has shown promising preclinical results, with plans to advance to clinical trials [19][20] Q&A Session All Questions and Answers Question: What are the gating factors to start patient dosing in the COVID-19 program? - Management indicated that the stop work order lifting allowed for immediate discussions with BARDA, and patient screening is currently underway, with dosing expected to start soon [37][39] Question: What does a positive outcome look like for the Phase 1 norovirus study? - Success is defined as the new constructs trending better than the old constructs on key immunogenicity endpoints, although statistical significance may not be achievable due to the study size [41][42] Question: What impact did the stop work order have on the expected timeline for the COVID-19 study? - The stop work order had a minor impact, but the company is now reactivating study sites and screening participants, with a projected six-month enrollment period once dosing begins [60][62] Question: Are there ongoing discussions for partnerships related to the norovirus program? - Management confirmed active discussions with a range of companies, with expectations that these will accelerate following the release of top-line results [65][66]